Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

M
W-071
Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials

Favorite
W-102
Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model

Favorite
M-004
MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.

Favorite
M-071
Mechanistic mathematical model of emicizumab

Favorite
T-051
Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases

Favorite
W-107
Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions

Favorite
W-131
Mechanistic modeling to inform T cell engager development for low copy targets

Favorite
T-137
Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients

Favorite
W-047
Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design

Favorite
M-024
Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.

Favorite
T-025
Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species

Favorite
M-076
Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)

Favorite
M-044
MIDD Platform of VZV Vaccine Immunogenicity and Efficacy

Favorite
M-048
mipdtrial: an open-source R package for simulating model-informed precision dosing trials

Favorite
T-045
Mixed effect state space model application for data driven pharmacometrics modeling

Favorite
M-070
Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose

Favorite
M-087
Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Favorite
T-097
Model Predictive Control Regulates Blood Pressure During Simulated Kidney Replacement Therapy

Favorite
T-109
Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders

Favorite
T-141
Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Favorite
W-051
Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations

Favorite
W-014
Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients

Favorite
W-083
Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)

Favorite
M-027
Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients

Favorite
M-042
Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection

Favorite
W-121
Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function

Favorite
T-053
Modeling and inter-species scaling of plasma DHO as a biomarker to inform first-in-human dose selection for a novel DHODH inhibitor

Favorite
M-088
Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics

Favorite
W-104
Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli

Favorite
W-089
Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach

Favorite
T-138
Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials

Favorite
T-085
Modeling progression and treatment of mCRPC using the Thales QSP software platform

Favorite
W-010
Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents

Favorite
T-140
Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy

Favorite
T-095
Modeling the Role of Organ Crosstalk and Cellular Adaptation in Multiple Organ Dysfunction Syndrome

Favorite
T-052
Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study

Favorite
T-123
Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections

Favorite